000275626 001__ 275626
000275626 005__ 20240229154944.0
000275626 0247_ $$2doi$$a10.1007/s00259-023-06243-y
000275626 0247_ $$2pmid$$apmid:37099131
000275626 0247_ $$2ISSN$$a1619-7070
000275626 0247_ $$2ISSN$$a0340-6997
000275626 0247_ $$2ISSN$$a1432-105X
000275626 0247_ $$2ISSN$$a1619-7089
000275626 0247_ $$2altmetric$$aaltmetric:146763971
000275626 037__ $$aDKFZ-2023-00828
000275626 041__ $$aEnglish
000275626 082__ $$a610
000275626 1001_ $$0P:(DE-He78)69d2d5247c019c2a2075502dc11bf0b2$$aSachpekidis, Christos$$b0$$eFirst author$$udkfz
000275626 245__ $$aThe prognostic value of [18F]FDG PET/CT based response monitoring in metastatic melanoma patients undergoing immunotherapy: comparison of different metabolic criteria.
000275626 260__ $$aHeidelberg [u.a.]$$bSpringer-Verl.$$c2023
000275626 3367_ $$2DRIVER$$aarticle
000275626 3367_ $$2DataCite$$aOutput Types/Journal article
000275626 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1688562514_17040
000275626 3367_ $$2BibTeX$$aARTICLE
000275626 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000275626 3367_ $$00$$2EndNote$$aJournal Article
000275626 500__ $$a#EA:E060#LA:E060# / 2023 Jul;50(9):2699-2714
000275626 520__ $$aTo investigate the prognostic value of [18F]FDG PET/CT as part of response monitoring in metastatic melanoma patients treated with immune checkpoint inhibitors (ICIs).Sixty-seven patients underwent [18F]FDG PET/CT before start of treatment (baseline PET/CT), after two cycles (interim PET/CT) and after four cycles of ICIs administration (late PET/CT). Metabolic response evaluation was based on the conventional EORTC and PERCIST criteria, as well as the newly introduced, immunotherapy-modified PERCIMT, imPERCIST5 and iPERCIST criteria. Metabolic response to immunotherapy was classified according to four response groups (complete metabolic response [CMR], partial metabolic response [PMR], stable metabolic disease [SMD], progressive metabolic disease [PMD]), and further dichotomized by response rate (responders = [CMR] + [PMR] vs. non-responders = [PMD] + [SMD]), and disease control rate (disease control = [CMR] + [PMR] + [SMD] vs. [PMD]). The spleen-to-liver SUV ratios (SLRmean, SLRmax) and bone marrow-to-liver SUV ratios (BLRmean, BLRmax) were also calculated. The results of PET/CT were correlated with patients' overall survival (OS).Median patient follow up [95% CI] was 61.5 months [45.3 - 66.7 months]. On interim PET/CT, the application of the novel PERCIMT demonstrated significantly longer survival for metabolic responders, while the rest criteria revealed no significant survival differences between the different response groups. Respectively on late PET/CT, both a trend for longer OS and significantly longer OS were observed in patients responding to ICIs with metabolic response and disease control after application of various criteria, both conventional and immunotherapy-modified. Moreover, patients with lower SLRmean values demonstrated significantly longer OS.In patients with metastatic melanoma PET/CT-based response assessment after four ICIs cycles is significantly associated with OS after application of different metabolic criteria. The prognostic performance of the modality is also high after the first two ICIs cycles, especially with employment of novel criteria. In addition, investigation of spleen glucose metabolism may provide further prognostic information.
000275626 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000275626 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000275626 650_7 $$2Other$$aImmune checkpoint inhibitors (ICIs)
000275626 650_7 $$2Other$$aImmunotherapy
000275626 650_7 $$2Other$$aMetabolic response criteria
000275626 650_7 $$2Other$$aMetastatic melanoma
000275626 650_7 $$2Other$$aTreatment response evaluation
000275626 650_7 $$2Other$$a[18F]FDG PET/CT
000275626 7001_ $$0P:(DE-He78)7dc85735e114a4ace658ba1450a2cca6$$aWeru, Vivienn$$b1$$udkfz
000275626 7001_ $$0P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aKopp-Schneider, Annette$$b2$$udkfz
000275626 7001_ $$aHassel, Jessica C$$b3
000275626 7001_ $$0P:(DE-He78)b2df3652dfa3e19d5e96dfc53f44a992$$aDimitrakopoulou-Strauss, Antonia$$b4$$eLast author$$udkfz
000275626 773__ $$0PERI:(DE-600)2098375-X$$a10.1007/s00259-023-06243-y$$n9$$p2699-2714$$tEuropean journal of nuclear medicine and molecular imaging$$v50$$x1619-7070$$y2023
000275626 909CO $$ooai:inrepo02.dkfz.de:275626$$pVDB
000275626 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)69d2d5247c019c2a2075502dc11bf0b2$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000275626 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7dc85735e114a4ace658ba1450a2cca6$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000275626 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000275626 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b2df3652dfa3e19d5e96dfc53f44a992$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000275626 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000275626 9141_ $$y2023
000275626 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2022-11-23$$wger
000275626 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2022-11-23$$wger
000275626 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-23
000275626 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-23
000275626 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NUCL MED MOL I : 2022$$d2023-08-23
000275626 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-23
000275626 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-23
000275626 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-23
000275626 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-23
000275626 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-23
000275626 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-23
000275626 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-08-23
000275626 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-23
000275626 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J NUCL MED MOL I : 2022$$d2023-08-23
000275626 9202_ $$0I:(DE-He78)E060-20160331$$kE060$$lE060 KKE Nuklearmedizin$$x0
000275626 9201_ $$0I:(DE-He78)E060-20160331$$kE060$$lE060 KKE Nuklearmedizin$$x0
000275626 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x1
000275626 9200_ $$0I:(DE-He78)E060-20160331$$kE060$$lE060 KKE Nuklearmedizin$$x0
000275626 980__ $$ajournal
000275626 980__ $$aVDB
000275626 980__ $$aI:(DE-He78)E060-20160331
000275626 980__ $$aI:(DE-He78)C060-20160331
000275626 980__ $$aUNRESTRICTED